Antios Therapeutics

Antios Therapeutics is a clinical-stage biopharmaceutical company headquartered in the United States. Established in 2018, the company is dedicated to developing groundbreaking therapies for viral diseases. With a committed and skilled leadership team, Antios Therapeutics focuses on advancing its lead oral drug candidate for a potentially curative treatment of HBV infections. The company recently received a significant boost with a $75.00M Series B investment on 03 November 2021. The investment round saw participation from notable firms including Pontifax, Domain Associates, Altium Capital, Avego Bioscience Capital, EPIQ Capital Group, GordonMD Global Investments, Amzak Health Investors, GRA Venture Fund, LLC, Heartland Healthcare Capital, and Fonds de solidarité FTQ. Antios Therapeutics' dedication to advancing innovative therapies for viral diseases coupled with the substantial investment in its Series B round positions the company as a noteworthy player in the biopharmaceutical and biotechnology industries. The company's significant progress and extensive investor backing indicate a promising outlook for its future in addressing critical unmet medical needs in the field of antiviral therapeutics.